Show simple item record

dc.contributor.authorOmer, Saad B.
dc.contributor.authorClark, Dayna R.
dc.contributor.authorAqil, Anushka R.
dc.contributor.authorTapia, Milagritos D.
dc.contributor.authorNunes, Marta C.
dc.contributor.authorKozuki, Naoko
dc.contributor.authorSteinhoff, Mark C.
dc.contributor.authorMadhi, Shabir A.
dc.contributor.authorWairagkar, Niteen
dc.date.accessioned2018-03-09T15:25:10Z
dc.date.available2018-03-09T15:25:10Z
dc.date.issued2018
dc.identifier.citationOmer, SB, et al. (2018). Maternal Influenza Immunization and Prevention of Severe Clinical Pneumonia in Young Infants: Analysis of Randomized Controlled Trials Conducted in Nepal, Mali, and South Africa. Pediatric Infectious Disease Journal, (Publish Ahead of Print), DOI: 10.1097/INF.0000000000001914, PMID: 29443825en_US
dc.identifier.urihttp://hdl.handle.net/10713/7547
dc.descriptionTrial Registration: The three trials were registered with ClinicalTrials.gov (trial numbers NCT01430689, NCT01034254, NCT02465190).en_US
dc.description.abstractBackground: To evaluate the effect of antenatal influenza vaccination on all-cause severe infant pneumonia, we performed pooled analysis of three randomized-controlled trials conducted in Nepal, Mali, and South Africa. Methods: The trials were coordinated from the planning phase. The follow-up period was 0–6 months post-partum in Nepal and Mali, and 0-24 weeks in South Africa. Pregnant women with gestational age 17-34 weeks in Nepal, ≥28 weeks in Mali, and 20-36 weeks in South Africa were enrolled. Trivalent Inactivated Influenza Vaccine (IIV). was compared with either saline placebo (Nepal and South Africa) or quadrivalent meningococcal conjugate vaccine (MCV) (Mali). In South Africa, cases were hospitalized, and were therefore considered to have severe pneumonia. In Nepal and Mali, severe infant pneumonia diagnosis was based on the WHO Integrated Management of Childhood Illness (IMCI) definition. Results: A total of 10,002 mothers and 9,801 live-born eligible infants were included in the present analysis. Incidence rate of severe pneumonia was 31% lower in the IIV group compared to the control group (incidence rate ratio [IRR]: 0.69, 95% CI: 0.50 - 0.94, P = 0.02). During periods with high influenza circulation there was lower incidence of severe pneumonia among the IIV group (IRR: 0.20, 95% CI: 0.06 - 0.74, P = 0.02), however, there was no difference in pneumonia incidence between study groups during periods of low and no influenza circulation. Conclusions: Maternal influenza immunization may reduce severe pneumonia episodes among infants –particularly those too young to be completely vaccinated against S. pneumoniae and influenza.en_US
dc.description.urihttps://dx.doi.org/10.1097/INF.0000000000001914en_US
dc.language.isoen_USen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.subject.meshInfant, Newborn--immunologyen_US
dc.subject.meshInfluenza, Human--prevention & controlen_US
dc.subject.meshInfluenza Vaccinesen_US
dc.subject.meshPneumonia--prevention & controlen_US
dc.subject.meshPregnancy--immunologyen_US
dc.subject.meshMalien_US
dc.subject.meshNepalen_US
dc.subject.meshSouth Africaen_US
dc.titleMaternal Influenza Immunization and Prevention of Severe Clinical Pneumonia in Young Infants: Analysis of Randomized Controlled Trials Conducted in Nepal, Mali, and South Africaen_US
dc.typeManuscripten_US
dc.description.urinameFull Texten_US
refterms.dateFOA2019-02-19T17:59:03Z


Files in this item

Thumbnail
Name:
MT_Maternal Influenza Immunization ...
Size:
1.861Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record